Close
Anne–Marie Langevin, MD
NOTE : If you're an existing patient, please connect via MyChart
-
About Me
About Anne–Marie Langevin, MD
Gender
- Female
Languages Spoken
- French
- Spanish
- Urdu
-
Credentials
Credentials
Certifications
- American Board of Pediatrics/Hematology-Oncology
Education
- Medical School: University of Montreal
- Internship: Hôpital Maisonneuve-Rosemont, Montreal, Canada
- Residency:
- Hospital Maisonneuve Rosemont
- Hotel Dieu de Montreal Hospital Ste Justine
- Fellowship:
- Hospital for Sick Children
- University of North Carolina Hospital
- Locations & Contact
-
Research & Publications
Research & Publications
Zoledronic acid therapy for recurrent giant cell tumor of the C2 vertebra in an adolescent.
Bartanusz, V., Ziu, M., Jimenez, D. F., Crownover, R. L. & Langevin, A. M.
Spine J. 1;15(8):1886-7 (2015). PMID: 25817726
Hemophagocytic lymphohistiocytosis in Texas: observations on ethnicity and race.
Niece, J.A., Rogers, Z.R., Ahmad, N., Langevin, A.M. & McClain, K.L.
Pediatr Blood Cancer 54(3):424-8 (2010). PMID:19953651
Characterization of Localized Osteosarcoma of the Extremity in Children, Adolescents, and Young Adults From a Single Institution in South Texas.
Sugalski, A. J., Jiwani, A., Ketchum, N. S., Cornell, J., Williams, R., Heim-Hall, J., Hung, J. Y. & Langevin, A. M.
J. Pediatr. Hematol. Oncol. 36(6):e353-8 (2014). PMID: 24487915; PMCID: PMC4222611
-
Clinical Trials
Clinical Trials
Type of Cancer
Multiple Sites
ClinicalTrials.gov Identifier
NCT02932280
Principal Investigator
Anne–Marie Langevin MD
POE16-01, A Phase I/II Study of Neratinib in Pediatric Patients with Relapsed/Refractory Solid Tumors or Hematologic Malignancies
The purpose of this study is to test the safety of neratinib at different dose levels and to find out what effects, good and bad, it has on the patients and the cancer.
Type of Cancer
Lymphoma, Lymphoid Leukemia
ClinicalTrials.gov Identifier
ClinicalTrials.gov registration not required
Principal Investigator
Anne–Marie Langevin MD
AALL1731: A Phase 3 Trial Investigating Blinatumomab (NSC# 765986) in Combination With Chemotherapy in Patients With Newly Diagnosed Standard Risk or Down Syndrome B-Lymphoblastic Leukemia (B-ALL) and the Treatment of Patients With Localized B-Lymphobl...